22 hrs ago
Opko Health CEO Phillip Md Et Al Frost Purchases 11,400 Shares
Opko Health CEO Phillip Md Et Al Frost acquired 11,400 shares of Opko Health stock on the open market in a transaction that occurred on Friday, August 15th.
Sun Aug 17, 2014
Opko Health CEO Purchases $174,472 in Stock
Opko Health CEO Phillip Md Et Al Frost acquired 19,300 shares of the company's stock in a transaction dated Thursday, August 14th.
Fri Aug 15, 2014
Insider Buying: Opko Health CEO Purchases 19,300 Shares of Stock
Opko Health CEO Phillip Md Et Al Frost acquired 19,300 shares of the stock in a transaction that occurred on Thursday, August 14th.
Tue Aug 12, 2014
OPKO Health's (OPK) CEO Phillip Frost on Q2 2014 Results - Earnings Call Transcript
Greetings and welcome to the OPKO Health Top-Line Rayaldee Results and Second Quarter 2014 Financial Results Conference Call.
Opko Health Sees Strong Trading Volume Following Better-Than-Expected Earnings
Shares of Opko Health saw unusually-high trading volume on Tuesday following a better than expected earnings announcement, Analyst Ratings News reports.
Mon Aug 11, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
This trial is one of two identical randomized, double... )--Enterprise Products Partners L.P. today announced that W. Randall Fowler, executive vice president and chief financial officer of Enterprise's general partner, ... )--AVEO Oncology today reported its second quarter 2014 financial results and provided an update on its progress toward ... (more)
OPKO Announces Second Quarter Operating and Financial Results
OPKO Health, Inc. , a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its second quarter ended June 30, 2014.
Thu Aug 07, 2014
OPKO Submits IND for Rayaldeea as Adjunctive Cancer Therapy
The initial investigation described in this IND is a phase 1 dose titration study designed to evaluate the safety and tolerability of Rayaldee in patients with breast or prostate cancer that has metastasized to bone who are receiving treatment with zoledronic acid or denosumab .
OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014...
OPKO Health, Inc. will announce top line data from the first of two identical pivotal Phase 3 clinical trials for RAYALDEE and its second-quarter 2014 financial results on Monday, August 11, 2014, after the market closes.
Wed Aug 06, 2014
Frost Museum of Science construction on schedule
A $35 million donation by the couple launched construction of the museum, which is targeted to open in 2016.
Mon Aug 04, 2014
Opko Health CEO Acquires $216,750 in Stock
Opko Health CEO Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock on the open market in a transaction dated Friday, August 1st.
Mon Jul 28, 2014
Opko Health CEO Phillip Md Et Al Frost Buys 36,000 Shares
Opko Health CEO Phillip Md Et Al Frost bought 36,000 shares of Opko Health stock on the open market in a transaction that occurred on Friday, July 25th.
Weekly CEO Buys Highlight: OPK, LJPC, SFNC, HAFC, TUBE
According to GuruFocus Insider Data , these are the largest CEO buys during the past week.
Wed Jul 23, 2014
Opko Health Stock Price Up 3.7% After Insider Buying Activity
Shares of Opko Health rose 3.7% on Wednesday after an insider bought additional shares in the company, Stock Ratings Network reports.
Tue Jul 22, 2014
Opko Health, Inc. Granted Patent From U.S. Patent & Trademark Office For RAYALDEE
OPKO Health, Inc. , a multinational biopharmaceutical and diagnostics company, today announced that the United States Patent and Trademark Office granted OPKO a patent covering RAYALDEEa , the Company's product to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.